Abstract: A cell death inducer for mast cells, a preventive/therapeutic agent for diseases in which mast cells are implicated, having a fusion protein including a PTD and an MITF variant as an active ingredient and a fusion protein comprises a His Tag, a PTD, and an MITF variant, wherein the MITF variant being an MITF mi variant, wh variant, HLH fragment, or A-type N-terminal region (1-305) fragment, and the PTD being a TAT-derived peptide; DNA coding for the fusion protein; and a method for preparing the fusion protein using genetic engineering techniques. Actions of the fusion protein of the present invention include inhibiting an activity of endogenous MITF by translocating into mast cells, inhibiting a survival of mast cells derived from precursor cells, and inducing cell death (apoptosis) in mature mast cells.

Abstract: A cell death inducer for mast cells, a preventive/therapeutic agent for diseases in which mast cells are implicated, having a fusion protein including a PTD and an MITF variant as an active ingredient and a fusion protein comprises a His Tag, a PTD, and an MITF variant, wherein the MITF variant being an MITF mi variant, wh variant, HLH fragment, or A-type N-terminal region (1-305) fragment, and the PTD being a TAT-derived peptide; DNA coding for the fusion protein; and a method for preparing the fusion protein using genetic engineering techniques. Actions of the fusion protein of the present invention include inhibiting an activity of endogenous MITF by translocating into mast cells, inhibiting a survival of mast cells derived from precursor cells, and inducing cell death (apoptosis) in mature mast cells.